Ieq Capital LLC raised its stake in Becton Dickinson and Co (NYSE:BDX) by 19.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,040 shares of the medical instruments supplier’s stock after acquiring an additional 333 shares during the period. Ieq Capital LLC’s holdings in Becton Dickinson and were worth $469,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Wealth Quarterback LLC acquired a new position in Becton Dickinson and in the fourth quarter valued at approximately $7,588,711,000. FMR LLC boosted its position in shares of Becton Dickinson and by 4.1% during the fourth quarter. FMR LLC now owns 13,465,704 shares of the medical instruments supplier’s stock worth $3,662,267,000 after buying an additional 528,037 shares during the period. State Street Corp boosted its position in shares of Becton Dickinson and by 1.7% during the fourth quarter. State Street Corp now owns 11,450,583 shares of the medical instruments supplier’s stock worth $3,114,215,000 after buying an additional 186,285 shares during the period. Geode Capital Management LLC boosted its position in shares of Becton Dickinson and by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 3,692,242 shares of the medical instruments supplier’s stock worth $1,001,837,000 after buying an additional 124,664 shares during the period. Finally, Fiera Capital Corp boosted its position in shares of Becton Dickinson and by 6.0% during the fourth quarter. Fiera Capital Corp now owns 3,454,596 shares of the medical instruments supplier’s stock worth $939,547,000 after buying an additional 194,629 shares during the period. Institutional investors own 85.38% of the company’s stock.

Several equities analysts have recently issued reports on the company. Cowen downgraded Becton Dickinson and from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $306.00 to $275.00 in a research report on Thursday, February 6th. Raymond James boosted their price objective on Becton Dickinson and from $283.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. KeyCorp reissued a “hold” rating on shares of Becton Dickinson and in a report on Tuesday, May 12th. SVB Leerink reissued a “market perform” rating and set a $262.00 target price (up previously from $245.00) on shares of Becton Dickinson and in a report on Friday, May 8th. Finally, UBS Group boosted their target price on Becton Dickinson and from $260.00 to $265.00 and gave the stock a “neutral” rating in a report on Friday, May 8th. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $275.79.

Shares of NYSE BDX traded down $0.45 during trading on Friday, hitting $258.25. The company had a trading volume of 1,988,044 shares, compared to its average volume of 2,074,950. The company has a market cap of $71.07 billion, a P/E ratio of 77.79, a PEG ratio of 2.60 and a beta of 0.95. Becton Dickinson and Co has a 52 week low of $197.75 and a 52 week high of $286.72. The business’s 50-day moving average is $247.89 and its 200 day moving average is $255.16. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.23. The company had revenue of $4.25 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The firm’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.59 earnings per share. On average, research analysts expect that Becton Dickinson and Co will post 10.68 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $0.79 dividend. The ex-dividend date is Monday, June 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.22%. Becton Dickinson and’s dividend payout ratio is currently 27.05%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: How does a security become overbought?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.